Lv43
572 积分 2024-05-28 加入
Population Pharmacokinetics and Pharmacodynamics Modeling for the Use of Recaticimab in Healthy Volunteers and Patients with Hypercholesterolemia
23天前
已完结
Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects
29天前
已完结
Predicting Clinical Pharmacokinetics/Pharmacodynamics and Impact of Organ Impairment on siRNA‐Based Therapeutics Using a Mechanistic Physiologically‐Based Pharmacokinetic‐Pharmacodynamic Model
30天前
已完结
Mechanistic Pharmacokinetics and Pharmacodynamics of GalNAc-siRNA: Translational Model Involving Competitive Receptor-Mediated Disposition and RISC-Dependent Gene Silencing Applied to Givosiran
1个月前
已完结
Potential Novel RNA-Targeting Agents for Effective Lipoprotein(a) Lowering: A Systematic Assessment of the Evidence from Completed and Ongoing Developmental Clinical Trials
1个月前
已完结
The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of N-Acetylgalactosamine–Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human
1个月前
已完结
Prediction of Interspecies Translation for Targeting Delivery Coefficients of GalNAc-siRNA Silencing Apolipoprotein C-III Using a Mechanistic Minimal Physiologically Based Pharmacokinetic/Pharmacodynamic Model
3个月前
已完结
Physiologically Based Pharmacokinetic Model‐Informed Drug Development for Polatuzumab Vedotin: Label for Drug‐Drug Interactions Without Dedicated Clinical Trials
3个月前
已完结
Why Do the Majority of Submissions for Bridging from a Prefilled Syringe to an Autoinjector Include Bioequivalence Studies in Order to Demonstrate Comparability?
3个月前
已完结
A Review of Recent FDA-Approved Biologic-Device Combination Products
3个月前
已完结
皖公网安备34019202002308
